Study of Investigational Drug in Osteoporosis (MK-0217-908)

Exclusion Criteria

• •participated in another therapeutic trial with an investigational compound within 30 days of randomization.
• •history of hypersensitivity to any component of ibandronate tablets or has hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
• •an abnormality of the esophagus which delays esophageal emptying such as stricture or achalasia.
• •unable to stand or sit upright for at least 60 minutes once a month.
• •current use of illicit drugs, or history of drug or alcohol abuse within the past five years.
• •has any of the following: hypocalcemia; any severe malabsorption syndrome; moderate or severe hypertension which is uncontrolled; new onset angina or myocardial infarction within six months of entry into the study; evidence for impaired renal function; organ transplantation; or other significant end organ diseases (genitourinary, cardiovascular, endocrine, hepatic, psychiatric, renal, hematologic, or pulmonary).
• •history of or evidence of metabolic bone disease (other than postmenopausal bone loss).
• •clinical fracture in the past year.
• •is receiving or has received treatment prior to randomization which might influence bone turnover.
• •is receiving or expected to receive during the course of the study any medication (other than study medication) which might alter bone or calcium metabolism, including Vitamin A in excess of 10,000 IU per day or Vitamin D in excess of 5000 IU per day, calcitonin, phenytoin, heparin, or lithium.